Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 18/20 | 0.64 |
| ▸ | EGFR | P00533 | 12/20 | 0.64 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
| ▸ | STK10 | O94804 | 1/20 | 0.56 |
| ▸ | RET | P07949 | 1/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.56 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.56 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.56 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.56 |
| ▸ | RPS6KA6 | Q9UK32 | 1/20 | 0.56 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | BRAF | P15056 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22009945 | 0.94 | KDR (0.57) | KDREGFR | |
| SCHEMBL3528731 | 0.81 | KDR (0.68) | KDREGFR | |
| SCHEMBL17974205 | 0.75 | NPC1 (0.44) | — | |
| SCHEMBL5654317 | 0.75 | EGFR (0.65) | KDREGFRGAKRIPK2STK10 | |
| SCHEMBL31067662 | 0.75 | EGFR (0.82) | KDREGFR | |
| SCHEMBL5473733 | 0.74 | KDR (0.74) | KDREGFRGAKRIPK2STK10 | |
| SCHEMBL6609814 | 0.74 | NAMPT (0.52) | — | |
| SCHEMBL3529674 | 0.74 | AURKB (0.74) | KDREGFRRETIRAK4 | |
| SCHEMBL31067640 | 0.73 | KDR (0.84) | KDREGFRGAKRIPK2STK10 | |
| SCHEMBL31067650 | 0.73 | KDR (0.83) | KDREGFRBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-12-17 | — | — | US | disclosed |
| EP-3415501-B9 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-12-02 | — | — | EP | disclosed |
| EP-3415501-B1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2020-04-08 | — | — | EP | disclosed |
| US-10501442-B2 | Quinoline derivative | ONO PHARMACEUTICALS CO., LTD. (JP) | 2019-12-10 | — | — | US | disclosed |
| US-20190135785-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-05-09 | — | — | US | disclosed |
| US-10208022-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2019-02-19 | — | — | US | disclosed |
| EP-3415501-A1 | QUINOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2018-12-19 | — | — | EP | disclosed |
| US-20180258072-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| US-9994549-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170088542-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-03-30 | — | — | US | disclosed |
| US-9573935-B2 | Quinoline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-02-21 | — | — | US | disclosed |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3026045-A1 | QUINOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392110-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KDR 27/4885EGFR 17/4885GAK 290/4885 |
| US-10501442-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | KDR 27/4885EGFR 17/4885GAK 290/4885 |
| US-20180258072-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KDR 27/4885EGFR 17/4885GAK 290/4885 |
| US-10208022-B2 | Quinoline derivative | FLT3, AXL, ERBB2 | KDR 27/4885EGFR 17/4885GAK 290/4885 |
| US-20160168121-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KDR 65/4885EGFR 24/4885GAK 223/4885 |
| US-20170088542-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KDR 27/4885EGFR 17/4885GAK 290/4885 |
| US-20190135785-A1 | QUINOLINE DERIVATIVE | FLT3, AXL, ERBB2 | KDR 27/4885EGFR 17/4885GAK 290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.